🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchHas anyone dealt with trial endpoint primer? Page 2

Has anyone dealt with trial endpoint primer?

BariatricNurseD Sun, Dec 28, 2025 at 4:35 AM 7 replies 1,032 viewsPage 2 of 2
PeptideSynthNJ
Member
234
1,234
Aug 2024
Princeton, NJ
Dec 28, 2025 at 10:39 AM#6
BariatricNurseD said:
Relative and absolute effects need reading together.

Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:

  1. Point estimate (HR/RR/OR) — center of the diamond
  2. Confidence interval width — precision of the estimate
  3. I² statistic — heterogeneity across studies
  4. Individual study weights — are results driven by one large trial?
  5. Prediction interval — range of plausible true effects in future settings

The the trial evidence meta-analysis shows a pooled RR of 0.72 (95% CI 0.65-0.82), I²=30%. This is a robust and consistent effect.

22 0wanda_boise, NurseAsh_DET, BenResearch_OR and 19 others
Reply Quote Save Share Report
alex_tucson
Member
567
2,345
May 2024
Tucson, AZ
Dec 28, 2025 at 1:02 PM#7

One thing that is still open after Dr.PeteFamMed’s answer:

How long did you give it before you decided it was working?

23 1labquiet_amy, emily_PDX, Dr.SleepRoch and 20 others
Reply Quote Save Share Report
Dr.SportsMedIN
Senior Member
1,456
6,789
Feb 2024
Indianapolis, IN
Dec 28, 2025 at 3:25 PM#8
PeptideSynthNJ said:
Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to: Point estimate (HR/RR/OR) —…

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 18,000 GLP-1 users vs matched controls showed reduced MI incidence (HR 0.78) over 4 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
24 2adam_van, Dr.SurgeonPGH, rachel_ABQ and 21 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
BariatricNurseD
Senior Member
1,678
7,234
Feb 2024
Dallas, TX
Online
Dec 28, 2025 at 5:48 PM#9

Reporting back.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.

25 3tom_AK, josh_phd_bmore, roxy_nash and 22 others
Reply Quote Save Share Report
MikeKY_noInsulin
Member
267
1,234
Oct 2024
Louisville, KY
Dec 29, 2025 at 5:15 AM#10
Dr.SportsMedIN said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

Last edited: Dec 29, 2025 at 8:15 AM
15 13bbq_ray_KC, oliver_london, tane_welly and 12 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register